All right. Well, great. Thank you guys for being here. We are going to get started with our next session. My name is Matt Hagood. I am on the research team here at UBS, working with Michael We are excited to welcome our next presenting company, Damora Therapeutics, and we have the team here, guys.
Thanks for being here. Maybe you want to give a quick introduction and then some background on Damora and the progress you have made this year and kind of the mutCALR space that you are working in. It would be great. Thanks.
Yeah. Just quickly for introductions, I am Jennifer Jarrett, and I am the CEO of Damora Therapeutics.
I am Sherwin Sattarzadeh today. I am the Chief Operating Officer.
Background on Damora. We are a Fairmount company. We are actually the sixth company that was founded by Fairmount. I am sure you guys are familiar with a lot of the other Fairmount companies. I think they are up to like 11 or 12, or definitely double digits now. But we were founded specifically to focus on hematological diseases, and our initial focus is on the myeloproliferative neoplasm space.
Myeloproliferative neoplasm is a group of blood cancers. The two that we are focusing on is essential thrombocythemia, which is when a patient produces too many platelets, and myelofibrosis, which is when a patient cannot produce healthy blood cells. And so these patients tend to be either anemic or neutropenic, et cetera.
The specific mutation that we are focusing on is something called the CALR mutation, and it is a key driver of disease in patients with those two diseases, essential thrombocythemia and myelofibrosis. In fact, one-third of patients with those two diseases have this mutation. It is a very prevalent mutation, and there is about 45,000 patients in the U.S. alone that have that mutation. That translates into a TAM in the U.S. of over $10 billion.
Our lead molecule is something called DMR-001. It was a molecule that was created by Paragon. For those of you that do not know Paragon is a company that is wholly owned by Fairmount. All they do is make antibodies. For most of the Fairmount companies that you know about, Oruka, Spyre, Apogee, et cetera, all of their antibodies came from this platform.
This platform, I think, now has a very well-deserved reputation for creating best-in-class antibodies, and we believe that DMR-001 is also a best-in-class antibody. Like I said, DMR-001 targets the CALR mutation. As a result, it is blocking the key underlying cause of disease in patients that have this mutation. It just entered a phase I study a few months ago. The study is now open in Australia and the U.S.
We are going to open in several other countries over the next few months. It is going to be a very big p hase 1/1b study from a site perspective, and our goal, obviously, is to get the phase I in well as quickly as possible and to be able to start a phase III by the middle of 2028. We are very excited about what we are doing.
We have a lot of questions, I know, that are teed up.
Yeah.
Specifically about DMR-001, so I will stop there.
Yeah, absolutely. No, it's
We'll take questions.
It's a really exciting space. Obviously, we just saw an acquisition yesterday from another mutCALR program, so there's a lot of investor enthusiasm in the space. I wanted to ask if you could talk a little bit about what we've seen so far from mutCALR-directed drugs that kind of validates this as a target across different indications, and yeah, we can go from there.
Yeah. Stepping back in time, in ASH 2022, which was when the first presentation was made at a major medical meeting on this target, at that meeting, Incyte presented preclinical data for their antibody that targets the CALR mutation. This was an oral presentation to a packed audience, and it was the first time that a preclinical data presentation got an oral at ASH.
It made a huge splash, and what they showed there was obviously just preclinical data validating this pathway and the fact that this is a very important pathway with a very large percentage of patients with MPNs. Then in 2025 was when they presented their first initial clinical data at EHA. Stepping back to ASH, it was when Paragon saw that preclinical data at ASH that they recognized the two major liabilities with INCA033989.
First was that it had a very suboptimal PK profile, which resulted in a very short half-life. That is why that drug needs to be given every two weeks by IV administration. The second major liability that they identified was that while their drug bound well to the Type 1 mutation, which is one of the types of mutations with patients that have mutCALR, it did not bind nearly as well to the Type 2 mutation. That has played out in the clinic.
Going back to the data that was presented at EHA in 2025, this was the first data set that was presented in essential thrombocythemia, and the data looked very, very good in Type 1 patients, but much less active in patients with Type 2 disease. Exactly what you expected to see based on the preclinical data.
That said, there was so much excitement around this data presentation that Incyte actually experienced an $8 billion increase in market cap just based on this data presentation at EHA in the middle of 2025, which just shows how much potential people saw in this class of therapies. What they are now showing is about an 80% response rate in Type 1 patients with ET, but only about a 50% response rate in patients with Type 2 disease.
In myelofibrosis, they are seeing a similar pattern where they are seeing about half the response rates in patients with the Type 2 mutation relative to patients with the Type 1 mutation. As I mentioned earlier, they are also having to administer their drug every two weeks by IV administration, and we have a much better form of administration.
The Incyte data is what has convinced everybody that this is a very validated and a very effective pathway. The other thing that they have shown is this is a very well-tolerated mechanism. Patients are staying on drug for very long periods of time. In the case of the ET data set in particular,
They are really seeing no AEs that stand out, so that is another thing that people really like about this class of therapies. But that is the data set that, like I said, has convinced everybody that this is a very promising class of therapies for the treatment of these diseases.
Perfect. You guys are in phase I now. I want to talk about the phase I study and design, eventually what you are going to show mid-year next year. But first, could you just talk about the design of your drug, how it is different from the Incyte molecule, and what you have done to make this an optimal therapy and how your drug could be a better therapy?
Yeah. As I mentioned, when Paragon saw this preclinical data in 2022, that was when they started work on our drug, DMR-001. The two main things that they were solving for is a better PK profile and longer half-life, and then much better activity against the Type 2 mutation. It actually took them three years to get to what is now DMR-001. The big challenge was significantly dialing up the Type 2 activity while retaining activity against the Type 1 mutation.
We think for anybody that's coming from behind, they are going to have the same challenge. Paragon, one of the best antibody development companies in the world, still took them three years to get to a really good molecule against this mutation, which I think tells you how difficult it is to develop a good drug against this mutation.
In terms of the two major benefits that our drug has as a result of all the work that Paragon did is our drug can be administered every four weeks subcutaneously. Actually, we're starting in the clinic day one with an every four-week subcutaneous administration. We'll ultimately develop this drug in an auto-injector pen, so very similar technology that you're used to from the GLP-1s and autoimmune disease drugs.
The other major benefit of our drug is that it, pre-clinically, has much better activity against the Type 2 mutation, and we expect that to play out in the clinic as well. For those of you who are wondering how big is that Type 2 mutation patient population, if you look at the patients that were enrolled in the Incyte study so far, it's about 55% of the ET patients and about 40% of the MF patients.
It's a very, very large patient population. Obviously, it's much more optimal to have a drug that treats all patients versus only works well in Type 1 or only works well in Type 2. We think the major advantage of our drug is that it's pan-mutant, and the goal of this drug is to work equally well in Type 2 as in Type 1.
You guys have some data coming up at ASH, actually, where I think you're showing this. Not just Type 1, Type 2, but even there are some smaller subsets of mutations too, where you think you're active too. Can you just talk about maybe the poster presentation you'll have at ASH coming up?
Yeah. We have some data that is coming up in a poster for ASH. There we are showing the activity of DMR-001 versus a reference antibody, which we believe is Incyte’s INCA033989. Since Incyte’s patent is published for INCA033989, we can basically synthesize their molecule.
We have done a head-to-head comparison pre-clinically, and what we have shown in 10 different mutations, so it includes Type 1 and Type 2, as well as eight different mutations that fall between Type 1 and Type 2, that our drug is much more active relative to INCA033989.
We did three different experiments against every mutation. We did not want to just do one experiment. Sometimes you can get an outlier of a result, but here we did three for every single mutation. You will see in that poster the increase in potency that we got across those mutations.
We have already disclosed that the average was 95 x, which is obviously a very significant improvement in potency, and we think that that demonstrates very clearly that this is a drug that clearly has much better pan-mutant activity relative to what we think INCA033989 has.
Perfect. phase I study is underway now. Could you just talk about the design? We have talked a little bit about what you are hoping to do with the design to get to find the optimal dose going across ET and MF. Talk about the design, what we will be able to show when we have data mid-year. Yeah.
Yeah. Why do I turn it over to Sherwin?
Yeah. It is a phase I, phase Ib study that is open now in Australia and in the U.S., and we will be, as Jennifer mentioned, opening the study in a number of other countries over the next few months. It is set up to move quickly through dose escalation, so we can get to expansion cohorts and build out a data set more broadly.
We have done this in a few different ways where the Bayesian study design allows you to, as you dose escalate and clear dose levels, enrich lower dose level cohorts with a broader patient population. Again, allowing you to move quickly and broadly at the same time. It includes ET and MF patients together in dose escalation.
We were able to get a 100 mg starting dose every four weeks subQ, which is a significantly higher starting dose than what INCA033989 was able to do as the first program in this class to go through regulatory reviews. That 100 mg is projected to be within the therapeutic range,
We do not expect to need too many dose levels to get through dose escalation before we can expand. Once we identify a dose and are able to put it into expansions, we can have several expansions running at the same time, looking at specifically ET, MF, and different subtypes of patients as well.
Yeah. Can you talk a little bit about the subtypes you are going to take a look at across ET and MF, treatment experience, treatment naive, maybe in MF monotherapy versus combos with Jakafi. What could you have? What could you hope to show? Then maybe we can talk too about what would be a good result from that data.
Sure. The patient population initially coming into the study during dose escalation will be ones that have had at least one prior therapy or are intolerant and eligible for standard of care therapy. So it is going to include a patient population that is quite varied going into the expansions as well.
As we kind of look at the data set evolving over time, the dose escalation portion of the study, when we look to present the data initially next year, it will be from the early part of the study, and we are going to want to look at across the populations that we have been looking at.
When you look at the cadence with which these patients demonstrate benefit or clinical response, the ET population certainly has an earlier readout than what the MF patients that require 12 weeks or so to get a scan and certainly demonstrate that spleen volume reduction.
The early signals we want to see is the translation of our preclinical profile into a clinical activity, pan-mutant activity, seeing the translation of some of the PK data into what we'll see in the clinic with a longer half-life, less frequent dosing.
I mean, you mentioned some of what Incyte has shown in ET. Do you think it would be fair to kind of benchmark against that Incyte data, and especially on the Type 2 side, to show that we really are looking at pan-mutant activity? Then from there, to what extent can we extrapolate that forward to MF and those populations as well?
What's nice is, the bars in ET are relative, I'm sorry, for Type 2 disease, both in ET and MF, are relatively low. What they showed again in ET is that in Type 2 patients, at their highest dose, they were getting to a 50% hematological response rate, and that actually included an incomplete response.
That feels like the bar from an ET perspective. Then MF, it's even a lower bar. JAK-inexperienced patients in Type 2, they were seeing about a 30% SVR, 35. Then at the other end of the spectrum, in Type 2 patients that had prior JAK, they were seeing only a 5% response rate.
Again, what's nice about those is those are pretty low bars, and obviously the lower the bar, I think the faster it is to be able to show an improvement over what they've shown in their clinical data.
I wanted to take a step back just for a second, focus on ET, then maybe we can talk about MF. But just on ET, I think people are not, like don't know this area as well as MF. Could you just talk about how this is treated normally, and what the opportunity is, what this market could look like for you guys?
Yeah. So really stepping back, so ET, as you said, I think is less well-known. These are patients that have very, very high platelet counts, or they have platelets that just don't function well. As a result, these patients are at very high risk of either thrombotic events or bleeding events, because these platelets aren't always functioning like they should.
On top of that, because we have these high-level platelets, they have a whole range of really serious symptoms, so very bad migraines, a lot of fatigue, a lot of pain, tingling in their hands and feet. So, the more we learn about ET, I think the more we appreciate that the symptom burden these patients experience is really high. On top of that, these patients have a fairly high risk of transforming to myelofibrosis.
For patients with a CALR mutation, their risk of transforming to myelofibrosis is actually much higher than in patients with other mutations. So for a lot of patients, that's almost what they fear the most and what really drives their desire to get treatment, is something that slows the progression of their disease and prevents them from progressing to myelofibrosis. Once you have myelofibrosis, that's when your overall survival becomes significantly shortened.
One of the reasons why there's so much interest in this class of therapies is because people believe that this is a disease-modifying class of therapy and should reduce the likelihood of progressing to myelofibrosis. The current treatment option today that most patients get is HYDREA, which is basically a chemotherapeutic agent. So all that does is basically kills all your blood cells.
While that does bring your platelet levels down, it obviously does nothing as far as really modifying the course of disease or slowing the progression of the disease to myelofibrosis. So that is why there's so much interest in this class of therapies, not just in the clinician community,
We've been surprised on how well-educated the patient community is on the class of therapy and how motivated they are to get into a clinical study for a mutCALR drug. And we hear all the time from sites that they have waiting lists for patients that want to get on a study for this class of therapies, which is obviously great for us as we're now enrolling our clinical study.
A significant population here treated with HYDREA, basically chemotherapy for their disease. This would be kind of a disease-modifying therapy. Should we think about this as like a chronic therapy, or is it more you go into a remission? Talk about the framework there. Maybe that's why the subQ profile matters, and just talk about kind of how that plays into this.
Yeah. So this is a disease. Once you're diagnosed, you will have this disease for life, and it's progressive over time. So, your disease is never going to get better. It may stay the same, but generally, it will get worse over the course of your life. So as a result, particularly for ET, where these patients do still live for like 20, 25 years, convenience is very, very important. And so right now, INCA033989 is being administered every two weeks as an IV infusion,
Patients are having to come into the infusion clinic to get treated there. So having an every four-week subQ option that could be done at home obviously would be very advantageous. And we hear all the time, these patients live like hours away from the clinic. It's really difficult for them to come into the clinic every two weeks.
Again, I think it just speaks to the attractiveness of having a much more convenient option that patients can take at home, particularly given this is a chronic disease, and these patients are seeing their clinician probably only three months typically. So, for them to have to go in every two weeks to an infusion center is a major inconvenience for them.
Yeah. Then shifting gears to myelofibrosis, there is a standard of care there already, JAK inhibitors. We talked a bit about kind of like what you would maybe hope to show in second line.
I mean, maybe just talk again in second line and then in frontline patients, and then you have monotherapy and you have combination. How should we think about comparing to Jakafi, to the new Incyte INCA033989, which is their CALR, and like how to think about that MF data?
Yeah. Maybe to start, one thing is that the current treatment options, Jakafi, momelotinib, et cetera. Jakafi specifically works less effectively on mutCALR patients than it does in patients with the JAK2 mutation. We know just even from Jakafi's EU label that the response rate for spleen volume reduction in non-JAK mutated patients is about half of that with the other patients.
Again, a high urgency to treat patients that have this particular mutation with a disease-modifying agent. We've seen from JAK inhibitors as well, they don't really have the same effect on reducing the molecular burden of the disease. It's really just directed at spleen volume reduction, symptom improvement, and for the first time, this class of mutant CALR drugs is able to perhaps change the course of their disease.
When you think about that in the context of patients who have maybe even milder myelofibrosis, the intermediate low-risk population that are really just a watch and wait right now, that's a pretty tough position for a patient to be in, that they're not sick enough to get treatment, your disease needs to progress to a place where the only treatment option you do have is still not going to ultimately change the course of your disease.
With this class of drugs, we have an opportunity to do that differently. The current sort of demonstration of benefit that we have from mutCALR is with INCA033989, where they've shown nice reductions in spleen volume, primarily in the frontline population, their JAK-ineligible population has a really nice response rate.
Again, you see that differential in the Type 1 versus the non-type one patients, as Jennifer was mentioning, particularly in the relapsed refractory myelofibrosis patients, where you have a very low response rate in the non-type one patients. Again, the opportunity here with the pan-mutant activity of DMR-001 is the opportunity to bring a better level of care, a better level of outcomes for both patient populations.
Maybe, like philosophically, do you feel like you need to combine with a JAK inhibitor given that you're kind of going after the underlying driver mutation here already?
Yeah, no. I mean, the idea there is that if you have an agent that can treat the underlying cause of the disease, the addition of that sort of more symptom-directed therapy would not be necessary there.
Now, I think one of the things we're learning and continue to learn with more data coming at ASH with INCA033989 is, did the response deepen over time, right? We'll be interested to see how that plays out, particularly on the TSS endpoint, if there is some improvement over time. The question still remains, what is the additive benefit of combining with ruxolitinib versus not?
I think the advantage we have is we can look at not just ruxolitinib, we can look at potential other agents to combine with as well, if there is that additive advantage, which again, shouldn't need to be there if you have a really good mutCALR-directed antibody.
Maybe, I think what I heard you say is maybe there's benefit on not just SVR, but particularly on TSS, which is the symptom score in myelofibrosis too, combining with either JAK or another type of agent. Is that kind of how you guys are thinking about it right now?
As the data matures, I think that'll help our thinking around that. I think we also need to be mindful of the disease-modifying endpoints or measurements that we can have with this agent as well, with improvements in anemia, improvements with blast counts, improvements with VAF. These are all things that we're going to be looking at to see if those deepen over time with these therapies.
Incyte will have some, what they, I think, we call true frontline data instead of kind of pseudo-frontline JAK-ineligible at ASH this year. Is there anything that you guys are looking for as you look across that data to kind of validate or tell you about the opportunity here for your drug in CALR?
I think the main thing is, are they going to go with a combination versus monotherapy in their phase III in the frontline setting, will be the main thing. Depending on when they've spoken, they've indicated one or both, or just doing like a three-arm study, which I think for them would be time-consuming and a much bigger study.
We'll see what the data shows and whether they feel comfortable enough going with a monotherapy strategy. Again, the big issue is just that lack of activity in Type 2 patients, which then dilutes the activity across the broader patient population in their study. I think that for them is their issue in going with a monotherapy strategy.
The other thing that we're interested in seeing that they've been talking about is, it sounds like they're getting deepening responses over time, which is what we would expect with this class of therapies, and obviously, it's good for everybody. That's another piece of their data that we're very interested in seeing.
Maybe just stepping back broadly in terms of the competitive landscape, there are others kind of working in this space. There are other mCALRs. One was acquired yesterday. There are other people working, including Lilly, working on a broader JAK-type targeted approach.
Can you just talk about where you feel you're positioned in the competitive landscape relative to the other players? There's also a J&J bispecific. We can maybe talk about that approach too, but just how do you feel about your lead drug here?
Yeah. We have the most advanced, half-life-extended, pan-mutant CALR antibody in the clinic, period. Anything else that is pan-mutant is behind us. Calytrix, which was the company that was acquired yesterday by Lilly, we think they are at least 12 months behind us. We will see if Lilly does some more work with their antibody, which could slow them down even more. We do think that they are materially behind us.
We are also not sure if they have anything better than what we have, particularly on the Type 1 side. It does seem like their activity against Type 2 will be similar to ours, but based on the own experiments that we have done, it is not clear that their Type 1 activity is as good as ours. You mentioned Incyte's next-gen drug.
That is also behind us, so we think that is at least six months behind us, maybe more than that. What is also important to note is that we have another antibody that is about to go into the clinic, which is DMR-002, which is an Fc-enhanced mutant CALR antibody.
That molecule will be in the clinic either before Incyte's next-gen molecule and, certainly before the Calytrix molecule. We will have two mutant CALR antibodies before Incyte's next gen, and then you look at Calytrix and they are now sort of third, fourth, or fifth. Not sure where,
Yeah.
In the clinic and,
Definitely.
We do have some time advantage.
I wanted to ask you about the second and third programs in your pipeline.
You have basically three different ways to target CALR in your pipeline. It is a whole portfolio, basically. How should investors think about the second and the third programs, the kind of like the patient segments that maybe those would be a good fit for, or if those are Yeah, just how do you think about them? I guess, that is,
Yeah. Just rewinding for a second, the reason we have three antibodies is because in that first data disclosure in the preclinical abstract or presentation in 2022, it was not clear if an Fc-null approach was going to work. Paragon set out to develop the Fc-enhanced antibody, DMR-002, as well as the T-cell engager program.
Fast-forward to today, we know that the Fc-null approach, particularly one that is going to have activity across the Type 1 and non-type one patients, should be the backbone of lifelong therapy for these patients. Now, there may be some patients who need a little bit more firepower because their disease is more advanced, for example.
That is where the DMR-002 program is really nicely situated to be in the clinic at the same time, where we can start to enroll patients that start to look at sort of where the activity of 001 makes sense, where the activity of 002 makes sense, and learn from those two programs to tailor them accordingly. I mean, 001 is our lead horse. We think that is going to treat the vast majority of patients.
If there are some sicker patients that need some immune activation that 002 brings, we will have that opportunity to test that as well. DMR-003 is our T-cell engager. You asked a question earlier about J&J's data. We were all waiting to see what exactly that looked like. As expected, you see the safety profile, 40% CRS rates, about 50% Grade 3 adverse events.
You're not seeing the response rates that perhaps we were expecting in this late-line ET population. We'll see what their MF data looks like, but I think it's a nice opportunity we have to learn from that and engineer our TCE to fill any gaps that they have. The interesting challenge is, how much more can you get out of a TCE that you won't get out of an Fc-null or an Fc-enhanced approach?
Sure. The Fc-enhanced entering the clinic, I think, this year. What are the timelines for the T-cell engager? It sounds like there may be even opportunities to tweak that as you learn from J&J. Basically, what are the timelines for that program?
We've guided towards a regulatory submission next year for the TCE program.
Great. And just to put a finer point on it, you think that those two programs are maybe more for refractory myelofibrosis? Is that kind of the right way to think about it?
I would say yes for the TCE. I think the 002 program, we will see what the safety profile. No one else has tested an Fc-enhanced antibody in this population. Depending on what that profile looks like, we can see how far that goes and to which patient populations that go.
Perfect. It is a good place to leave it. Exciting year ahead for Damora. First key data mid-year next year. Guys, thank you so much for being here.
Thank you. It was great to be here.
Thank you.